Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total revenue	$ 829,716	$ 616,933
Operating expenses
Research and development	2,813,491	1,217,556
General and administrative	2,663,657	1,701,448
Sales and marketing	899,252	282,277
Transaction costs		245,322
Impairment of right-of-use asset	55,496
Impairment of intangibles assets		750,596
Total operating expenses	7,090,934	4,611,419
Operating loss	(6,261,218)	(3,994,486)
Other (expense) income
Warrant inducement expense	(7,755,541)
Interest and other income	4,925	87,335
Interest expense	(1,164,982)	(38,267)
Foreign currency transaction losses	427,615	(3,876)
Change in fair value of derivative financial instruments	(101,390)
Total other (expense) income	(8,589,373)	45,192
Loss before income taxes	(14,850,591)	(3,949,294)
Provision for income taxes
Net loss	(14,850,591)	(3,949,294)
Net loss available to common stockholders	$ (14,850,591)	$ (3,949,294)
Net loss per common share - basic and diluted	$ (0.5)	$ (0.53)
Weighted average shares outstanding - basic and diluted	29,485,067	7,393,232
Net loss	$ (14,850,591)	$ (3,949,294)
Other comprehensive (loss) income - foreign currency translation	(1,078,479)	39,477
Comprehensive loss	(15,929,070)	(3,909,817)
Product sales [Member]
Revenue
Total revenue	613,918	366,933
Operating expenses
Cost of products and services	554,054	276,554
Laboratory services [Member]
Revenue
Total revenue	97,726
Operating expenses
Cost of products and services	104,984	137,666
Collaborations revenue [Member]
Revenue
Total revenue	$ 118,072	$ 250,000